research Heat Treatment Increases the Incidence of Alopecia Areata in the C3H/HeJ Mouse Model
Heat treatment increases hair loss in certain mice.
Search
for
Sort by
Research
390-420 / 1000+ results
research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
research JAK Inhibition in the Treatment of Alopecia Areata: A Promising New Dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Relapse in Alopecia Totalis After Successful Treatment with Intralesional Corticosteroid and Oral Immunomodulator
The patient's hair loss from alopecia totalis returned despite initial successful treatment.
research The Role of Micronutrients in Alopecia Areata: A Review
People with alopecia areata often have lower levels of vitamin D, zinc, and folate, but more research is needed to understand if supplements can help treat it.
research Prevention and Treatment of Alopecia Areata with Quercetin in the C3H/HeJ Mouse Model
Quercetin effectively treated and prevented hair loss in mice.
research Androgenetic Alopecia: A Review
Androgenetic alopecia is a common hair loss condition influenced by various factors and linked to psychosocial and cardiovascular issues.
research The Development and Validation of the Hair Shedding Visual Scale for Asian Women (HSVS-A)
The HSVS-A is an effective tool for quickly screening hair shedding in Asian women.
research A Case of Unusual Comedogenesis in Alopecia Totalis
A man with total hair loss developed blackhead-like spots on his scalp, possibly because no hair was present to help drain oils.
research Androgen Excess: Investigations and Management
The conclusion is that managing androgen excess requires long-term treatment, including hormonal contraceptives and androgen blockers, with follow-up after six months.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Letters to the Editor: Case Reports and Studies in Dermatology
Careful management of blood thinners is crucial for lupus patients with APS.
research Alopecia Areata: Good Response to Treatment with Fractional Laser in 5 Cases
Fractional laser treatment helped hair regrowth in patients with alopecia areata.
research Chemokine C-C Motif Ligand 7 (CCL7), a Biomarker of Atherosclerosis, Is Associated with the Severity of Alopecia Areata: A Preliminary Study
Higher levels of CCL7 are linked to more severe hair loss in alopecia areata patients.
research Ophiasis Pattern Alopecia Areata in an Infant
Early recognition and treatment of atypical alopecia areata in infants are crucial.
research The Effect of an Oral Product Containing Amla Fruit on Female Androgenetic Alopecia: A Randomized Controlled Trial
Amla fruit syrup improved hair growth and satisfaction in women with hair loss without significant side effects.
research Alopecia Areata in a Patient with WNT10A Heterozygous Ectodermal Dysplasia
A girl with a rare genetic condition affecting hair and nails also developed a common type of hair loss, suggesting a possible genetic link.
research A Systematic Review of Clinical Trials Using Single or Combination Therapy of Oral or Topical Finasteride for Women in Reproductive Age and Postmenopausal Women with Hormonal and Nonhormonal Androgenetic Alopecia
Oral and topical finasteride are effective and safe for treating female hair loss.
research Androgenetic Alopecia and Coronavirus Infection
COVID-19 may worsen hair loss, but treatments like minoxidil can help.
research Follicular Swiss Cheese Pattern: Another Histopathologic Clue to Alopecia Areata
Dilated follicular infundibula and increased catagen/telogen follicles are key indicators for diagnosing alopecia areata.
research A Prospective Study on the Efficacy of Platelet-Rich Plasma in Alopecia Areata
Platelet rich plasma is an effective treatment for alopecia areata.
research Revitalizing Effect on the Scalp After Injection with a Mechanically Stabilized Hyaluronic Acid Complex in Subjects with Androgenetic Alopecia
The treatment improved hair thickness, shine, and reduced hair loss effectively.
research Alopecia Areata: A Review of Disease Pathogenesis
Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
research Post-SARS-CoV-2 Acute Telogen Effluvium: An Expected Complication
Many COVID-19 patients experience temporary hair loss after infection, not linked to infection severity or treatment.
research Covid Induced Telogen Effluvium: An Insight
COVID-19 may cause temporary hair loss due to direct damage to hair follicles, but it usually gets better on its own.
research Recent Modalities in Treatment of Telogen Effluvium: Comparative Study
Both botulinum toxin A and multivitamin mesotherapy effectively treat hair loss, with botulinum toxin A being the better single-session option.
research A TP63 Mutation Causes Prominent Alopecia with Mild Ectodermal Dysplasia
A TP63 gene mutation causes significant hair loss and mild skin, nail, and tooth abnormalities.
research A Rare Case of Cutis Verticis Gyrata with Underlying Cerebriform Intradermal Nevus
A patient with a scalp condition and benign skin tumor experienced hair loss and did not improve with treatment, choosing not to have surgery despite a small cancer risk.
research Modified Platelet Rich Plasma Therapy for Alopecia Totalis
The combined treatment helps improve severe hair loss and reduces the need for other medications.
research Incidence and Prevalence of Alopecia Areata in the Australian Primary Care Setting: A Retrospective Analysis of Electronic Health Record Data
The analysis found that alopecia areata, a hair loss condition, is not very common in Australia, affecting about 0.13% of people, with new cases most often seen in males aged 19 to 34 years.